Pharma Deals and Investments
Pharma Deals and Investments
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
German chemicals and life sciences group Merck KGaA has completed its acquisition of the chromatography business of JSR Life Sciences, adding Protein A chromatography capabilities and a team of over 50 employees to its process solutions portfolio. The deal expands Merck's downstream purification offerings for monoclonal antibody production. Financial terms were not disclosed.
Biogen announced on March 31, 2026 that it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, adding Apellis’ rare‑disease drugs Empaveli and Syfovre to its portfolio. The deal expands Biogen’s rare‑disease pipeline as its multiple‑sclerosis revenues decline.
Kyntra Bio announced the completion of the sale of its FibroGen China assets to AstraZeneca, enabling full repayment of its senior secured term loan and extending its cash runway into 2028.
Gilead Sciences announced it will acquire privately held biotech Ouro Medicines for more than $2 billion, adding the experimental antibody OM336 to its immunology pipeline. The deal expands Gilead’s portfolio of autoimmune therapies as it seeks growth beyond its HIV...
Kyntra Bio completed the sale of its FibroGen China assets to AstraZeneca, enabling repayment of its senior secured term loan and extending its cash runway. The transaction was announced during Kyntra Bio's Q4 2025 earnings call on March 16, 2026.
Enodia Therapeutics announced it has acquired the Sec61‑based discovery and development assets of Kezar Life Sciences. The transaction includes an upfront payment of $1 million and potential milestone payments up to $127 million, plus royalties, bolstering Enodia’s targeted protein degradation platform and...
Cognito Therapeutics announced the closing of an oversubscribed $105 million Series C round led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from Apollo Health Ventures and Benvolio Group. The funding will support a pivotal data readout, regulatory filing...
The Administration for Strategic Preparedness and Response (ASPR) announced on March 5 that it will invest in Antheia, Inc., a Menlo Park‑based company, to produce thebaine domestically for pain management and opioid‑overdose reversal medications. The funding aims to reduce reliance on foreign...
Kairos Pharma announced it has signed a binding agreement to acquire the exclusive worldwide rights to the AI‑designed pan‑EGFR inhibitor CL‑273 from Celyn Therapeutics, a biotech backed by OrbiMed and Torrey Pines Investment. The acquisition expands Kairos’s oncology pipeline and...
Eton Pharmaceuticals announced it has in‑licensed the U.S. commercialization rights to Hemangeol®, the only FDA‑approved treatment for infantile hemangioma, from Pierre Fabre Medicament Sas. The acquisition, disclosed in early March 2026, will be financed with cash on hand and is...
Cigna announced the acquisition of CarepathRx, a private‑equity‑backed pharmacy that supplies prescription drugs to roughly 10% of U.S. hospitals. The deal expands Cigna’s vertical integration in the pharmaceutical supply chain, complementing its earlier purchase of Express Scripts.
Japanese drugmaker Asahi Kasei announced it will acquire German biotech Aicuris for €780 million, gaining its antiviral therapy pritelivir targeting HSV. The deal expands Asahi Kasei's anti‑infectives portfolio and supports its goal of reaching JPY 300 billion in pharma sales by 2030.
GlaxoSmithKline (GSK) announced the acquisition of privately held 35Pharma, a developer of a pulmonary arterial hypertension drug. The cash deal is valued at just under $1 billion, expanding GSK’s pipeline in respiratory and immunology.
